BTRX-335140

BTRX-335140
Clinical data
Other namesBTRX-140; CYM-53093; NMRA-140
Identifiers
IUPAC name
  • 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H32FN5O2
Molar mass453.562 g·mol−1
3D model (JSmol)
SMILES
  • CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
InChI
  • InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
  • Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N

BTRX-335140, also known as BTRX-140, CYM-53093, and NMRA-140, is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder.[1][2][3] As of February 2020, it is in phase 2 clinical trials for this indication.[2]

See also

References

  1. ↑ "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Retrieved 2020-01-25.
  2. 1 2 "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
  3. ↑ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.